Antisense Oligonucleotide Protein Therapy to Inhibit Increased Ki67 Expression in Oral Squamous Cell Carcinoma Patients
Oral cavity cancer is one of the most common neoplastic lesions of the head and neck. Relatively recent data suggest that the incidence of neoplastic lesions is quite high. In one study, out of 143 oral cavity tumors, 125 were malignant, of which 115 (92%) were oral squamous cell carcinoma which was ranked sixth in the world. One strategy that can be used is Antisense Oligonucleotide (ASO) which is a protein that hybridizes complementary mRNA sequentially in Watson-Crick base pairing. This protein is therapeutic in malignancy.